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METHOD AND MATERIAL
A group of 51 men with myocardial infarction have been treated continuously with estrogen for periods of 6 to 48 months (average, 24 months). Of these, 20 middle-aged males (mean age, 50.5 years) were studied before and at intervals up to 1 year after initiation of therapy with 5 to 20 mg. (average, 10 mg.) daily of oral mixed conjugated estrogens (Premarin). This drug was selected for its freedom from production of nausea and vomiting, which permitted long-term administration. Twenty similar patients (mean age, 48.5 years) received placebo tablets and served as a group for comparison. The estrogen-treated and control groups were comparable as to incidence of angina pectoris, myocardial infarction, congestive heart failure, hypertension, and diabetes.
The effects of estrogen therapy were explained to both the patient and his wife, and their consent was obtained for the treatment. This precaution minimized any subsequent psychologic difficulties.
Serum cholesterol was determined with the acidiron reagent of Zlatkis, Zak, and Boyle,5 after hydrolysis and extraction according to Abell, Levy, Brodie, and Kendall.6 In our hands, this technic yielded cholesterol values averaging 53 ± 1 mg.
per cent lower than did the direct method of Zlatkis and co-workers (N = 350; s.d. = 22 mg. per cent). The high intrinsic sensitivity of the acid-iron reaction permitted convenient, routine cholesterol analyses on 0.2 ml. of serum.
Lipid phosphorus was estimated by a micromethod involving re-extraction with petroleumESTROGEN THERAPY FOR CORONARY ATHEROSCLEROSIS cording to Youngberg and Youngberg, 8 and determination of liberated inorganic phosphate according to Fiske and SubbaRow.9 Lipid phosphorus X 25 was taken as serum phospholipid.
The "a-" and "fl-" lipoprotein fractions of serum were separated by zone electrophoresis, by means of the filter paper "sandwich" technic described by Kunkel and Slater.10 After migration the papers were cautiously air-dried below 60 C., and narrow strips were taken for staining with bromphenol blue (proteins) and oil red 0 (lipids). The areas on the unstained strips corresponding to the a-lipid (albumin plus a,-globulin) and p3-lipid (d3-globulin) zones were removed separately, the lipids were eluted with chloroform-methanol (3:1), the solvent was removed in vacuo, the residues were re-extracted with petroleum ether, and the cholesterol content of aliquots of the final extracts was determined with the acid-iron reagent.
For 24 months in all patients on a dose of 10 mg. or more of Premarin daily. Some degree of potency has returned to 3 patients who had received 10 mg. daily for 6 to 24 months before withdrawal of therapy. There has been no evidence to date of a return of fertility in these patients, although circumstances of age prevent an adequate appraisal. The most distressing effect to the patients was gynecomastia, which was minimal (tenderness and slight swelling) in most of the patients and moderate in only 2. The tenderness usually subsided within a few months. An unexpected observation was the growth of new scalp hair in 4 bald patients. The only cardiac complication to the therapy was the appearance of pulmonary edema in 2 patients, which did not respond to digitalis and diuretics, but did subside promptly on omitting the estrogen.
It is clear that the control group showed no significant alteration in serum cholesterol (fig. 1) or phospholipid ( fig. 2 ) during the year of observation. The estrogen-treated group showed a decrease of cholesterol, of borderline significance statistically, by the end of 3 months ( fig. 1 ). Figure 2 shows the strikingly significant increase of phospholipid in the treated group, from 207 mg. per cent to 248 mg. per cent at 3 months. This increase was maintained to 12 months. Figure 3 demonstrates that the C/P ratio in the estrogen-treated group, initially 1.30, was significantly decreased to 1.14 at 1 month, further decreased at 3 months to 0.96, and maintained thereafter to 1 year. The C/P ratio of the control group was essentially unchanged.
The distribution of serum cholesterol in the a-and ,B-lipoprotein fractions as per cent of total cholesterol is shown in figure 4. The control group showed no significant changes during the 1-year Figure 6 shows the changes observed in urinary 17-ketosteroids. It will be seen that in all instances the changes observed in the control group did not differ significantly from zero. This was also true of the total 17-ketosteroid output in the estrogen-treated group. However, the daily excretion of dehydroisoandrosterone was increased during estrogen therapy from 0.8 to 1.6 mg., while the excretion of androsterone and of etiocholanolone was areola. An excellent cosmetic effect has been achieved, and no breast hypertrophy has followed this procedure. It eliminates the psychologic effects of gynecomastia and avoids any possibility of malignant disease of the breast from estrogen stimulation.
In 3 patients in whom the loss of sexual potency was especially distressing the treatment was stopped. The serum lipids of 1 of these patients promptly reverted to abnormal levels.
It should be noted that in spite of prolonged estrogen therapy the basic masculine psychologic traits of these patients have remained intact.
The development of acute pulmonary edema noted in 2 patients was thought to be due to the sodium-and water-retaining effect of estrogens. 16 The serum lipid data presented are in gen- 21 The relatively lower phospholipid values of the present study are reflected in the higher C/P ratios. By paper electrophoresis, significant changes in the percentage of cholesterol in the a-and f-fractions of the lipoproteins were demonstrated during estrogen therapy. It was found that approximately 75 per cent of the total serum cholesterol was recovered in these fractions. In studies now in progress, individual sera have been submitted to zone electrophoresis and ultracentrifugation at a solvent density of 1.063. The f-/a-lipoprotein cholesterol ratios determined by the 2 technics have shown close correspondence. These studies will be reported elsewhere. The change in 3-/oa-lipoprotein cholesterol ratios was very similar to that reported by Barr using the Cohn microfractionation method no. 10. 18 Barr's ratios changed from 7.8 to 3.7 in 4 weeks and the ratios presented here from 6.8 to 3.2 in 4 weeks. These represent identical decreases of 53 per cent.
It is noteworthy that despite the changes in excretion of individual 17-ketosteroids during estrogen therapy, there was no significant alteration in the mean output of total 17-ketosteroids. The excretion of dehydroisoandrosterone, presumably an "in-process" adrenal metabolite (Lieberman and Teich22), was increased during estrogen therapy. Similar data have been presented by A. M. Robinson. 23 The decreased excretion of androsterone and etiocholanolone is readily explained on the basis of diminished testosterone production by the Leydig cells of the testes. The serial testicular biopsy studies offer histologic confirmation of this finding. The relative constancy of excretion of the 11-oxygenated ketosteroids, metabolites of adrenal cortical origin, suggests that adrenal cortical function was not suppressed during estrogen therapy.
Thyroid function, as measured by the 24-hour uptake of a tracer dose of J'31, was not significantly altered after 1 
